Update on antivirals and vaccines for seasonal and potential pandemic use

References

• Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med.353, 1363–1373 (2005).
   PubMed Web of Science ®Google Scholar
• Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir. Ther.10(8), 901–910 (2005).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus ADME et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet355, 1845–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Kawai N, Ikematsu H, Iwaki N et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003–2004 and 2004–2005 influenza seasons. Clin. Infect. Dis.43, 439–444 (2006).
   PubMed Web of Science ®Google Scholar
• Kaye D. FDA staff urges psych warning for flu drug labels. Clin. Infect. Dis.46, III–IV (2008).
   Google Scholar
• The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet352(9144), 1877–1881 (1998).
   PubMed Web of Science ®Google Scholar
• Monto AS, Fleming DM, Henry D et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Infect. Dis.180, 254–261 (1999).
   PubMed Web of Science ®Google Scholar
• Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch. Intern. Med.160, 3234–3240 (2000).
   PubMedGoogle Scholar
• Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomized controlled trials. BMJ326, 1235 (2003).
   PubMed Web of Science ®Google Scholar
• Bowles SK, Lee W, Simor AE et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J. Am. Geriatr. Soc.50, 608–616 (2002).
   PubMed Web of Science ®Google Scholar
• Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch. Intern. Med.161, 212–217 (2001).
   PubMedGoogle Scholar
• de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. Dec 22, 353(25), 2667–2672 (2005).
   PubMed Web of Science ®Google Scholar
• Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet364(9436), 759–765 (2004).
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. Sep.13(9), 1354–1357 (2007).
   PubMed Web of Science ®Google Scholar
• Monto AS, McKimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother.50, 2395–2402 (2006).
   PubMed Web of Science ®Google Scholar
• Ciancio B, Fernandez de la Hoz K, Kreidl P et al. Oseltamivir resistance in human seasonal influenza viruses (A/H1N1) in EU and EFTA countries: an update. Eur. Surveill.13(6), (2008).
   Google Scholar
• Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z et al.; Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med.358(3), 261–273 (2008).
   PubMed Web of Science ®Google Scholar
• Bright RA, Medina M-J, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet366, 1175–1181 (2005).
   PubMed Web of Science ®Google Scholar
• Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA295, 891–894 (2006).
   PubMed Web of Science ®Google Scholar
• Cheung C-L, Rayner JM, Smith GJD et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis.193, 1626–1629 (2006).
   PubMed Web of Science ®Google Scholar
• Barr IG, Hurt AC, Deeda N, Iannello P, Tomasov C, Komadina N. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antiviral Res.75, 173–176 (2007).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Viboud C, Grenfell BT et al. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol.24(8), 1811–1820 (2007).
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Fang H-B, Tan M, Webster RG. Neuraminidase inhibitor–rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother.48, 4855–4863 (2004).
   PubMed Web of Science ®Google Scholar
• Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA. Amantadine–oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther.12(3), 363–370 (2007).
   PubMed Web of Science ®Google Scholar
• Ison MG, Gnann J, Nagy-Agren S et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther.8, 183–190 (2003).
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Ilyushina NA, Boltz DA et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother.51(4), 1414–1424 (2007).
   PubMed Web of Science ®Google Scholar
• Kaiser L, Wat C, Mills T et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med.163(14), 1667–1672 (2003).
   PubMed Web of Science ®Google Scholar
• Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm. Rep.53(RR-3), 1–36 (2004).
   PubMedGoogle Scholar
• Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin. Infect. Dis.39(9), 1300–1306 (2004).
   PubMed Web of Science ®Google Scholar
• Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA282, 31–35 (1999).
   PubMedGoogle Scholar
• Hayden FG, Atmar RL, Schilling M et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med.341, 1336–1343 (1999).
   PubMed Web of Science ®Google Scholar
• Hayden FG, Belshe R, Villanueva C et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J. Infect. Dis.189, 440–449 (2004).
   PubMed Web of Science ®Google Scholar
• Welliver R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA285, 748–754 (2001).
   PubMed Web of Science ®Google Scholar
• Monto AS, Pichichero ME, Blanckenberg SJ et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J. Infect. Dis.186, 1582–1588 (2002).
   PubMed Web of Science ®Google Scholar
• Peters PH Jr, Gravenstein S, Norwood P et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J. Am. Geriatr. Soc.49, 1025–1031 (2001).
   PubMed Web of Science ®Google Scholar
• Monto AS, Rotthoff J, Teich E et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin. Infect. Dis.39, 459–464 (2004).
   PubMed Web of Science ®Google Scholar
• Lowen AC, Palese P. Influenza virus transmission: basic science and implications for the use of antiviral drugs during a pandemic. Infect. Disord. Drug Targets7(4), 318–328 (2007).
   PubMedGoogle Scholar
• Subbarao K, Chen H, Swayne D et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology305(1), 192–200 (2003).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Shay DK, Haber P et al. Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Morb. Mortal. Wkly. Rep.56(RR06), 1–54 (2007).
   PubMedGoogle Scholar
• Treanor J, Wright PF. Immune correlates of protection against influenza in the human challenge model. Dev. Biol. (Basel)115, 97–104 (2003).
   PubMedGoogle Scholar
• Negri E, Colombo C, Giordano L et al. Influenza vaccine in healthy children: a meta-analysis. Vaccine23, 2851–2861 (2005).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Smith S, Demicheli V et al. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: a systematic review. Lancet365, 773–780 (2005).
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Jackson LA, Nelson J et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5–8-year-old children. J. Infect. Dis.194, 1032–1039 (2006).
   PubMedGoogle Scholar
• Groothuis JR, Lehr MV, Levin MJ. Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children. Vaccine12, 139–141 (1994).
   PubMedGoogle Scholar
• Park CL, Frank AL, Sullivan M, Jindal P, Baxter BD. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics98(2 Pt 1), 196–200 (1996).
   PubMed Web of Science ®Google Scholar
• Ritzwoller DP, Bridges CB, Shetterly S et al. Effectiveness of the 2003–2004 influenza vaccine among children 6 months to 8 years of age with 1 vs. 2 doses. Pediatrics116, 153–159 (2005).
   PubMed Web of Science ®Google Scholar
• Allison MA, Daley MF, Crane LA et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003–2004 season. J. Pediatr.149, 755–762 (2006).
   PubMed Web of Science ®Google Scholar
• Wilde JA, McMillan JA, Serwint J et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA281, 908–913 (1999).
   PubMed Web of Science ®Google Scholar
• Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost–benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA284, 1655–1663 (2000).
   PubMed Web of Science ®Google Scholar
• Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev.3, CD001269 (2004).
   Google Scholar
• Nichol KL, Lind A, Margolis KL et al. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med.333, 889–893 (1995).
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med.355, 2513–2522 (2006).
   PubMed Web of Science ®Google Scholar
• Herrera GA, Iwane MK, Cortese M et al. Influenza vaccine effectiveness among 50–64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003–2004. Vaccine25, 154–160 (2007).
   PubMed Web of Science ®Google Scholar
• Blumberg EA, Albano C, Pruett T et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin. Infect. Dis.22, 295–302 (1996).
   PubMed Web of Science ®Google Scholar
• Dorrell L, Hassan I, Marshall S et al. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int. J. STD AIDS8, 776–779 (1997).
   PubMed Web of Science ®Google Scholar
• Cates CJ, Jefferson TO, Bara AI, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst. Rev.2, CD000364 (2004).
   Google Scholar
• Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease [update]. Cochrane Database Syst. Rev.1, CD002733 (2006).
   PubMed Web of Science ®Google Scholar
• Govaert TM, Thijs CT, Masurel N et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA272, 1661–1665 (1994).
   PubMed Web of Science ®Google Scholar
• Nordin J, Mullooly J, Poblete S et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J. Infect. Dis.184, 665–670 (2001).
   PubMed Web of Science ®Google Scholar
• Hak E, Nordin J, Wei F et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin. Infect. Dis.35, 370–377 (2002).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti D, Rudin M et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet366, 1165–1174 (2005).
   PubMed Web of Science ®Google Scholar
• Hambidge SJ, Glanz JM, France EK. Safety of inactivated influenza vaccine in children 6 to 23 months old. JAMA296, 1990–1997 (2006).
   PubMed Web of Science ®Google Scholar
• Daubeney P, Taylor CJ, McGaw J et al. Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high-risk children aged 6 months to 4 years. Br. J. Clin. Pract.51, 87–90 (1997).
   PubMedGoogle Scholar
• American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N. Engl. J. Med.345, 1529–1536 (2001).
   PubMed Web of Science ®Google Scholar
• Bierman CW, Shapiro GG, Pierson WE et al. Safety of influenza vaccination in allergic children. J. Infect. Dis.136(Suppl.), S652–S655 (1977).
   Web of Science ®Google Scholar
• Bohlke K, Davis RL, Marcy SM et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics112, 815–820 (2003).
   PubMed Web of Science ®Google Scholar
• Fuller JD, Craven DE, Steger KA et al. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin. Infect. Dis.28, 541–547 (1999).
   PubMed Web of Science ®Google Scholar
• Amendola A, Boschini A, Colzani D et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J. Med. Virol.65, 644–648 (2001).
   PubMed Web of Science ®Google Scholar
• Sullivan PS, Hanson DL, Dworkin MS et al. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS14, 2781–2785 (2000).
   Google Scholar
• Lasky T, Terracciano GJ, Magder L et al. The Guillain–Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N. Engl. J. Med.339, 1797–1802 (1998).
   PubMed Web of Science ®Google Scholar
• Haber P, DeStefano F, Angulo FJ et al. Guillain–Barre syndrome following influenza vaccination. JAMA292, 2478–2481 (2004).
   PubMed Web of Science ®Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. Guillain–Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am. J. Epidemiol.110, 105–123 (1979).
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Stukel TA, Kwong J. Guillain–Barre syndrome after influenza vaccination in adults: a population-based study. Arch. Intern. Med.166, 2217–2221 (2006).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Fleming DM, Aristequi JF et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics118, 2298–2312 (2006).
   PubMed Web of Science ®Google Scholar
• Gaglani MJ, Piedra PA, Herschler GB et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold adapted influenza virus vaccine against the 2000–2001 influenza A(H1N1) and B epidemic in healthy children. Arch. Pediatr. Adolesc. Med.158, 65–73 (2004).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA282, 137–144 (1999).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med.356, 685–696 (2007); erratum in: N. Engl. J. Med.356, 1283 (2007).
   PubMed Web of Science ®Google Scholar
• Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J.23, 138–144 (2004).
   PubMed Web of Science ®Google Scholar
• FluMist [package insert]. Medimmune Vaccines, Inc., Gaithersburg, MD, USA (2007).
   Google Scholar
• Belshe RB, Nichol KL, Black SB et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin. Infect. Dis.39, 920–927 (2004).
   PubMed Web of Science ®Google Scholar
• King JC Jr, Treanor J, Fast PE et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J. Infect. Dis.181, 725–728 (2000).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Holmes SJ, Mendelman PM et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine17, 1905–1909 (1999).
   PubMed Web of Science ®Google Scholar
• Salgado CD, Gianetta ET, Hayden FG, Farr BM. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect. Control Hosp. Epidemiol.25, 923–928 (2004).
   PubMed Web of Science ®Google Scholar
• Sato M, Saito R, Tanabe N et al. Antibody response to influenza vaccination in nursing home residents and health-care workers during four successive seasons in Niigata, Japan. Infect. Control Hosp. Epidemiol.26, 859–866 (2005).
   Google Scholar
• Carman WF, Elder AG, Wallace LA et al. Effects of influenza vaccination of health-care personnel on mortality of elderly people in longterm care: a randomised controlled trial. Lancet355, 93–97 (2000).
   PubMed Web of Science ®Google Scholar
• Hayward AC, Harling R, Wetten S et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomized controlled trial. BMJ333, 1241 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas RE, Jefferson TO, Demicheli V, Rivetti D. Influenza vaccination for health-care workers who work with elderly people in institutions: a systematic review. Lancet Infect. Dis.6, 273–279 (2006).
   PubMedGoogle Scholar
• Veits J, Römer-Oberdörfer A, Helferich D et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine26(13), 1688–1696 (2008).
   Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet370(9587), 580–589 (2007).
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a Phase I randomised controlled trial. Lancet368(9540), 991–997 (2006).
   PubMed Web of Science ®Google Scholar
• Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet367(9523), 1657–1664 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Edwards KM, Dekker CL et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis.197(5), 667–675 (2008).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Bernhard R, Gérard P et al. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE3(2), e1665 (2008).
   PubMed Web of Science ®Google Scholar
• Meeting of the Immunization Strategic Advisory Group of Experts, November 2007 – conclusions and recommendations. Wkly Epidemiol. Rec.83(1), 1–15 (2008).
   PubMedGoogle Scholar
• Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet367(9509), 475–481 (2006).
   PubMed Web of Science ®Google Scholar
• Gao W, Soloff AC, Lu X et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol.80(4), 1959–1964 (2006).
   PubMed Web of Science ®Google Scholar
• Laddy DJ, Yan J, Corbitt N et al. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine25(16), 2984–2989 (2007).
   PubMed Web of Science ®Google Scholar
• Stoloff GA, Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur. J. Immunol.37(9), 2441–2449 (2007).
   PubMed Web of Science ®Google Scholar
• Itoh Y, Ozaki H, Tsuchiya H et al. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine26(4), 562–572 (2008).
   PubMedGoogle Scholar
• Sencer DJ, Millar JD. Reflections on the 1976 swine flu vaccination program. Emerg. Infect. Dis.12, 29–33 (2006).
   PubMed Web of Science ®Google Scholar
• Macroepidemiology of Influenza Vaccination (MIV) Study Group. The macroepidemiology of influenza vaccination in 56 countries, 1997–2003. Vaccine23, 5133–5143 (2005).
   PubMed Web of Science ®Google Scholar